Restricted accessResearch articleFirst published online 2019-08
Adiposity,Hepatic Triglyceride,and Carotid Intima Media Thickness During Behavioral Weight Loss Treatment in Antipsychotic-Treated Youth: A Randomized Pilot Study
The purpose of this pilot study was to evaluate changes in adiposity, carotid intima media thickness (CIMT), and hepatic fat content measured via magnetic resonance imaging-estimated hepatic proton density fat fraction (PDFF) in antipsychotic (AP)-treated youth versus nonpsychiatric (NP) participants during participation in a 16-week behavioral weight loss (BWL) intervention.
Subjects/Methods:
Overweight/obese AP-treated youth (n = 26) were randomized 2:1 to weekly treatment versus recommended care (RC) over 16 weeks. NP controls (n = 21) were assigned to weekly treatment. Dual-energy X-ray absorptiometry (DEXA)-measured adiposity, CIMT, and PDFF were measured at baseline and 16 weeks. Analyses assessed group differences in the effect of BWL on adiposity, CIMT, and PDFF.
Results:
BWL was well tolerated in both AP-treated and NP groups. DEXA-measured fat decreased significantly in the NP group (F[1,16] = 11.81, p = 0.003), with modest improvements in adiposity and hepatic fat in the AP-treated group, while an increase in adiposity was observed in the RC group. Significant differences in endpoint DEXA total fat (F[2,34] = 4.81, p = 0.01) and PDFF (F[2,30] = 3.60, p = 0.04) occurred across treatment groups, explained by larger improvements in NP versus RC youth in DEXA total fat (p = 0.03) and PDFF (p = 0.04).
Conclusions:
Intensive, family-based BWL treatment can improve whole-body adiposity and liver fat in obese youth, with decreases or attenuation of additional fat gain observed in AP-treated youth.
BarlowSE: Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: Summary report. Pediatrics 120(Suppl, 4):S164–S192, 2007.
3.
BaronciniLAV, SylvestreLC, BaronciniCV, PecoitsRF: Assessment of carotid intima-media thickness as an early marker of vascular damage in hypertensive children. Arq Bras Cardiol, 108:452–457, 2017.
4.
BirkenaesAB, BirkelandKI, EnghJA, FaerdenA, JonsdottirH, RingenPA, FriisS, OpjordsmoenS, AndreassenOA: Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J Clin Psychopharmacol, 28:132–137, 2008.
5.
BirnbaumHG, KesslerRC, LoweSW, SecnikK, GreenbergPE, LeongSA, SwensenAR: Costs of attention deficit-hyperactivity disorder (ADHD) in the US: Excess costs of persons with ADHD and their family members in 2000. Curr Med Res Opin, 21:195–206, 2005.
6.
CalargeCA, AcionL, KupermanS, TanseyM, SchlechteJA: Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. J Child Adolesc Psychopharmacol, 19:101–109, 2009.
7.
ColtonCW, ManderscheidRW: Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis, 3:A42, 2006.
8.
ConnorDF, CarlsonGA, ChangKD, DaniolosPT, FerzigerR, FindlingRL, HutchinsonJG, MaloneRP, HalperinJM, PlattnerB, PostRM, ReynoldsDL, RogersKM, SaxenaK, SteinerH: Juvenile maladaptive aggression: A review of prevention, treatment, and service configuration and a proposed research agenda. J Clin Psychiatry, 67:808–820, 2006.
9.
CorrellCU, ManuP, OlshanskiyV, NapolitanoB, KaneJM, MalhotraAK: Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA, 302:1765–1773, 2009.
10.
CorteseS, Moreira-MaiaCR, St FleurD, Morcillo-PenalverC, RohdeLA, FaraoneSV: Association between ADHD and obesity: A systematic review and meta-analysis. Am J Psychiatry, 173:34–43, 2016.
11.
CrystalS, OlfsonM, HuangC, PincusH, GerhardT: Broadened use of atypical antipsychotics: Safety, effectiveness, and policy challenges. Health Aff (Millwood), 28:w770–w781, 2009.
12.
DaumitGL, DickersonFB, WangNY, DalcinA, JeromeGJ, AndersonCA, YoungDR, FrickKD, YuA, GennusaJV3rd, OefingerM, CrumRM, CharlestonJ, CasagrandeSS, GuellarE, GoldbergRW, CampbellLM, AppelLJ: A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med, 368:1594–1602, 2013.
13.
DetkeHC, DelBelloMP, LandryJ, HoffmannVP, HeinlothA, DittmannRW: A 52-week study of olanzapine with a randomized behavioral weight counseling intervention in adolescents with schizophrenia or bipolar I disorder. J Child Adolesc Psychopharmacol, 26:922–934, 2016.
14.
EpsteinLH, PaluchRA, KilanowskiCK, RaynorHA: The effect of reinforcement or stimulus control to reduce sedentary behavior in the treatment of pediatric obesity. Health Psychol, 23:371–380, 2004.
15.
EpsteinLH, SquiresS: The Stoplight Eating Program for Children and Parents. Boston (Massachusetts), Little, Brown and Co., 1988.
HagstromerM, BergmanP, De BourdeaudhuijI, OrtegaFB, RuizJR, ManiosY, Rey-LopezJP, PhilippK, von BerlepschJ, Sjostrom M; HELENA StudyGroup: Concurrent validity of a modified version of the International Physical Activity Questionnaire (IPAQ-A) in European adolescents: The HELENA Study. Int J Obes (Lond) 32(Suppl, 5):S42–S48, 2008.
18.
HillAP, ZuckermanKE, FombonneE: Obesity and autism. Pediatrics, 136:1051–1061, 2015.
19.
KoskinenJ, MagnussenCG, SabinMA, KahonenM, Hutri-KahonenN, LaitinenT, TaittonenL, JokinenE, LehtimakiT, ViikariJS, RaitakariOT, JuonalaM: Youth overweight and metabolic disturbances in predicting carotid intima-media thickness, type 2 diabetes, and metabolic syndrome in adulthood: The Cardiovascular Risk in Young Finns study. Diabetes Care, 37:1870–1877, 2014.
20.
Le GrangeD, HughesEK, CourtA, YeoM, CrosbyRD, SawyerSM: Randomized Clinical trial of parent-focused treatment and family-based treatment for adolescent anorexia nervosa. J Am Acad Child Adolesc Psychiatry, 55:683–692, 2016.
21.
McIntyreRS, JerrellJM: Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. Arch Pediatr Adolesc Med, 162:929–935, 2008.
22.
MerikangasKR, HeJP, BrodyD, FisherPW, BourdonK, KoretzDS: Prevalence and treatment of mental disorders among US children in the 2001–2004 NHANES. Pediatrics, 125:75–81, 2010.
23.
MorratoEH, NicolGE, MaahsD, DrussBG, HartungDM, ValuckRJ, CampangaE, NewcomerJW: Metabolic screening in children receiving antipsychotic drug treatment. Arch Pediatr Adolesc Med, 164:344–351, 2010.
24.
MorrisonJA, FriedmanLA, Gray-McGuireC: Metabolic syndrome in childhood predicts adult cardiovascular disease 25 years later: The Princeton Lipid Research Clinics Follow-up Study. Pediatrics, 120:340–345, 2007.
25.
NewcomerJW: Metabolic considerations in the use of antipsychotic medications: A review of recent evidence. J Clin Psychiatry 68(Suppl, 1):20–27, 2007.
26.
NicolG, WorshamE, Haire-JoshuD, DuncanA, SchweigerJ, YingingM, LenzeE: Getting to more effective weight management in antipsychotic-treated youth: A survey of barriers and preferences. Child Obes, 12:70–76, 2016a.
27.
NicolGE, de Las FuentesL, RiekAE, Bernal-MizrachiC, LenzeEJ, MillerJP, SchweigerJA, YinglingMD, HuangVJ, DixonDJ, HennekensCH, NewcomerJW: Adiposity and cardiometabolic risk in children with and without antipsychotic drug treatment. J Clin Endocrinol Metab, 100:3418–3426, 2015.
28.
NicolGE, KolkoRP, MillsM, GunnarsdottirT, YinglingMD, SchweigerJA, LenzeEJ, NewcomerJW, WilfleyD: Behavioral weight loss treatment for youth treated with antipsychotic medications. Scand J Child Adolesc Psychiatry Psychol, 4:96–104, 2016b.
29.
NicolGE, YinglingMD, FlavinKS, SchweigerJA, PattersonBW, SchechtmanKB, NewcomerJW: Metabolic effects of antipsychotics on adiposity and insulin sensitivity in youths: A randomized clinical trial. JAMA Psychiatry, 75:788–796, 2018.
30.
NordentoftM, WahlbeckK, HallgrenJ, WestmanJ, OsbyU, AlinaghizadehH, GisslerM, LaursenTM: Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden. PLoS One, 8:e55176, 2013.
31.
OlfsonM, BlancoC, LiuL, MorenoC, LajeG: National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry, 63:679–685, 2006.
32.
OrenA, VosLE, UiterwaalCS, GorissenWH, GrobbeeDE, BotsML: Change in body mass index from adolescence to young adulthood and increased carotid intima-media thickness at 28 years of age: The Atherosclerosis Risk in Young Adults study. Int J Obes Relat Metab Disord, 27:1383–1390, 2003.
33.
OussenyZ, YingeQ, ThomasR, SteveS, SteveR, MassoloM, CroenLA: Healthcare service utilization and cost among adults with autism spectrum disorders in a U.S. integrated healthcare system. Autism Adulthood, 1, 2018.
34.
PathakP, WestD, MartinBC, HelmME, HendersonC: Evidence-based use of second-generation antipsychotics in a state medicaid pediatric population, 2001–2005. Psychiatr Serv, 61:123–129, 2010.
35.
QuattrinT, WilfleyDE: The promise and opportunities for screening and treating childhood obesity: USPSTF recommendation statement. JAMA Pediatr, 171:733–735, 2017.
36.
RaoG: Childhood obesity: Highlights of AMA Expert Committee recommendations. Am Fam Physician, 78:56–63, 2008.
37.
RogolAD, ClarkPA, RoemmichJN: Growth and pubertal development in children and adolescents: Effects of diet and physical activity. Am J Clin Nutr 72(2, Suppl):521S–528S, 2000.
38.
TannerJM: Fetus into Man: Physical Growth Form Conception to Maturity, revised edition. Cambridge (Massachusetts), Harvard University Press, 1989.
39.
TheimKR, SintonMM, GoldschmidtAB, Van BurenDJ, DoyleAC, SaelensBE, SteinRI, EpsteinLH, WilfleyDE: Adherence to behavioral targets and treatment attendance during a pediatric weight control trial. Obesity (Silver Spring), 21:394–397, 2013.
40.
TODAY Study Group: Design of a family-based lifestyle intervention for youth with type 2 diabetes: The TODAY study. Int J Obes (Lond), 34:217–226, 2010.
41.
WalkerER, McGeeRE, DrussBG: Mortality in mental disorders and global disease burden implications: A systematic review and meta-analysis. JAMA Psychiatry, 72:334–341, 2015.
42.
WilfleyDE, SaelensBE, SteinRI, BestJR, KolkoRP, SchechtmanKB, WallendorfM, WelchRR, PerriMG, EpsteinLH: Dose, content, and mediators of family-based treatment for childhood obesity: A multisite randomized clinical trial. JAMA Pediatr, 171:1151–1159, 2017.
43.
WilfleyDE, SteinRI, SaelensBE, MockusDS, MattGE, Hayden-WadeHA, WelchRR, SchechtmanKB, ThompsonPA, EpsteinLH: Efficacy of maintenance treatment approaches for childhood overweight: A randomized controlled trial. JAMA, 298:1661–1673, 2007.
44.
WunschR, de SousaG, ToschkeAM, ReinehrT: Intima-media thickness in obese children before and after weight loss. Pediatrics, 118:2334–2340, 2006.
45.
YoonY, WinkLK, PedapatiEV, HornPS, EricksonCA: Weight gain effects of second-generation antipsychotic treatment in autism spectrum disorder. J Child Adolesc Psychopharmacol, 26:822–827, 2016.
46.
ZhangJP, LenczT, ZhangRX, MittaM, MaayanL, JohnM, RobinsonDG, FleischhackerWW, KahnRS, OphoffRA, KaneJM, MalhotraAK, CorrellCU: Pharmacogenetic associations of antipsychotic drug-related weight gain: A systematic review and meta-analysis. Schizophr Bull, 42:1418–1437, 2016.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
